CXCL16 and neoplasm: Continuous administration of d-MAPPS increased concentration of CXCL16 in the tumor microenvironment (Figure 2(g)) and attracted tumoricidal, perforin, and granzyme-expressing CD8+CTLs (Figures 6(a) and 6(b)), CD4+Th1, and Th17 lymphocytes in the tumors of 4T1+d-MAPPS-treated mice (Figures 5(a) and 5(b)).